This project team will create a White Paper with recommendations for adverse event collection instructions, with a focus on Phase 2-4 clinical trials.  This White Paper will build upon a White Paper that outlines results from a survey on current practices, indicating variation that can likely be reduced.  Recommendations will be based on the desired end-in-mind, and may or may not be consistent with current practices

Project Leads:

Aimee Basileabasile@surfaceoncology.com
Mary Nilssonnilsson_mary_e@lilly.com